Alan Anh-Chuong Nguyen, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Immunoglobulins, Intravenous | 2 | 2020 | 652 | 0.670 |
Why?
|
Granulomatous Disease, Chronic | 1 | 2016 | 174 | 0.530 |
Why?
|
Thorax | 1 | 2016 | 547 | 0.460 |
Why?
|
Eosinophilia | 1 | 2016 | 541 | 0.420 |
Why?
|
Prednisone | 1 | 2016 | 1574 | 0.410 |
Why?
|
Immunologic Factors | 1 | 2020 | 1580 | 0.380 |
Why?
|
Immunologic Deficiency Syndromes | 2 | 2021 | 547 | 0.300 |
Why?
|
Anti-Inflammatory Agents | 1 | 2016 | 1790 | 0.290 |
Why?
|
Systemic Inflammatory Response Syndrome | 2 | 2021 | 612 | 0.270 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 2 | 2021 | 297 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3133 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3240 | 0.200 |
Why?
|
Antibody-Dependent Enhancement | 1 | 2020 | 16 | 0.190 |
Why?
|
Pandemics | 1 | 2020 | 8388 | 0.180 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2020 | 365 | 0.160 |
Why?
|
Immunization, Passive | 1 | 2020 | 623 | 0.150 |
Why?
|
Inflammation | 1 | 2016 | 10638 | 0.140 |
Why?
|
Immunomodulation | 1 | 2020 | 541 | 0.140 |
Why?
|
Lymphopenia | 1 | 2019 | 285 | 0.140 |
Why?
|
Severe Combined Immunodeficiency | 1 | 2019 | 223 | 0.140 |
Why?
|
Adaptive Immunity | 1 | 2020 | 713 | 0.130 |
Why?
|
Neonatal Screening | 1 | 2019 | 591 | 0.120 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1782 | 0.120 |
Why?
|
Biological Products | 1 | 2021 | 860 | 0.110 |
Why?
|
T-Lymphocytes | 2 | 2020 | 10180 | 0.100 |
Why?
|
Adrenal Cortex Hormones | 1 | 2020 | 1855 | 0.100 |
Why?
|
Phagocytosis | 1 | 2016 | 1539 | 0.100 |
Why?
|
Antiviral Agents | 1 | 2021 | 2987 | 0.090 |
Why?
|
Molecular Targeted Therapy | 1 | 2020 | 2727 | 0.080 |
Why?
|
Critical Care | 1 | 2021 | 2647 | 0.080 |
Why?
|
Immunity, Innate | 1 | 2020 | 2958 | 0.080 |
Why?
|
Gene Expression | 1 | 2020 | 7799 | 0.070 |
Why?
|
Child, Preschool | 4 | 2021 | 41006 | 0.060 |
Why?
|
Hospitalization | 1 | 2023 | 10262 | 0.060 |
Why?
|
Asthma | 1 | 2021 | 6011 | 0.060 |
Why?
|
Interleukin-6 | 2 | 2021 | 3200 | 0.050 |
Why?
|
Obesity | 1 | 2023 | 12745 | 0.050 |
Why?
|
Azetidines | 1 | 2021 | 142 | 0.050 |
Why?
|
Cohort Studies | 1 | 2023 | 40561 | 0.050 |
Why?
|
Macrophage Activation Syndrome | 1 | 2020 | 111 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 17446 | 0.040 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2020 | 426 | 0.040 |
Why?
|
Purines | 1 | 2021 | 594 | 0.040 |
Why?
|
Retrospective Studies | 2 | 2023 | 77449 | 0.040 |
Why?
|
Humans | 8 | 2023 | 744343 | 0.040 |
Why?
|
Child | 3 | 2021 | 77709 | 0.030 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 546 | 0.030 |
Why?
|
Interleukin-10 | 1 | 2020 | 1200 | 0.030 |
Why?
|
California | 1 | 2019 | 1402 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20129 | 0.030 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2020 | 1573 | 0.030 |
Why?
|
Host-Pathogen Interactions | 1 | 2021 | 1477 | 0.030 |
Why?
|
Sulfonamides | 1 | 2021 | 1938 | 0.030 |
Why?
|
Pyrazoles | 1 | 2021 | 1972 | 0.020 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 2282 | 0.020 |
Why?
|
Survival Analysis | 1 | 2021 | 10252 | 0.020 |
Why?
|
Male | 4 | 2021 | 350118 | 0.020 |
Why?
|
Cytokines | 1 | 2021 | 7322 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2021 | 9274 | 0.020 |
Why?
|
Prognosis | 1 | 2021 | 29063 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2019 | 25625 | 0.010 |
Why?
|
Infant | 1 | 2020 | 35136 | 0.010 |
Why?
|
Female | 3 | 2021 | 380194 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2021 | 63114 | 0.010 |
Why?
|
Risk Factors | 1 | 2021 | 72290 | 0.010 |
Why?
|
Adolescent | 1 | 2020 | 85781 | 0.010 |
Why?
|